Клинический случай применения Пиоглитазона при стероидном диабете у пациента с болезнью Иценко-Кушинга

Полный текст:

Список литературы

1. Дедов. И.И., Мельниченко Г.А., Фадеев В.В. Эндокринология: Учебник. М: Медицина, 2000.

2. Wang M. The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome. Nutrition and Metabolism, 2:3 doi: 10.1186/1743-7075-2-3, 2005.

3. Willi S.M., Kennedy A., Wallace P. et al. Troglitazone antagonizes metabolic effects of glucocorticoids in humans. Diabetes, Vol. 51, Oct 2002.

4. Weinstein S.P., Wilson C.M., Pritsker A. et al. Dexamethasone inhibits insulin- stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism 47: 3-6, 1998.

5. Laplante M., Sell H., MacNaul K.L. et al. PPAR-gamma activation mediates adi- pose deport-specific effects on gene expression and lipoprotein lipase activity. Diabetes, Vol. 52: 2003.

6. Kim H., Ahn Y. Role of peroxisome proliferators-activated receptor-gamma in the glucose-sensing apparatus of liver and beta-cells. Diabetes, Vol. 53, S1, 2004.

7. Nagi D.K., Vani D.H. Diabetic fatty liver. Diabetes UK. Diabetic Medicine, 22, 1-21, 2005.

8. Ferre P. The biology of peroxisome proliferators-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes, Vol. 53: S1, 2004.

9. Diabetes prevention program research group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403, 2002.

10. Jarvinen H. Insulin resistance in type 2 diabetes. Oxford, England: Blackwell, 2003: 22.1-22.19.

11. Jarvinen H. Tiazolidindiones; drug therapy. New Engl J Med 351: 1106-1118, 2004.

12. Desvergne B., Wahli W. Peroxisome proliferators-activated receptors: nuclear control of metabolism. Endocrine Reviews 20 (5): 649-688, 1999.

13. Miyazaki Y., Mahankali A., Matsuda M., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol and Metabol 87(6): 2784-2791, 2002.

14. Heaney A.P., Fernando M., Young W.H. et al. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nature Medicine, Vol. 8, 11:1281-1286, 2002.

15. Heaney A.P., Fernando M., Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Investigation, Vol. 111, 9:1381-1388, 2003.

16. Schaefer K.L., Wada K., Takahashi H. et al. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces apoptosis in hepatocellular carcinoma cells. Cancer Res. 2005 Mar 15; 65(6):2251-9.

17. Keshamouni V.G., Arenberg D.A., Reddy R.C. et al. PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia. 2005 Mar; 7(3):294-301.

18. Takashima T., Fujiwara Y., Hamaguchi M. et al.. Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma. Oncol Rep. 2005 Apr; 13(4): 601-6.

19. Ceni E., Mello T., Tarocchi M. et al. Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells. World J Gastroenterol. 2005 Feb 28; 11(8):1122-30.

20. Gruszka A., Kunert-Radek J., Pawlikowski M. Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro. Neuro Endocrinol Lett. 2005 Feb; 26(1):51-4.

21. Huang J.W., Shiau C.W., Yang Y.T. et al.Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol. 2005 Apr; 67(4):1342-8. Epub 2005 Jan 13.

22. Ambrosi B., Dall'Asta C., Cannavo S. et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing disease. Eur J of Endocrinology, Vol. 151: 173-178, 2004.

23. Hull S., Sheridan B., Atkinson A.B. Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syn- drome. J Clin Endocrinology, 62: 258-262, 2005.

24. Suri D., Weiss R.E. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab. 2005 Mar; 90(3):1340-6. Epub 2004 Dec 7.

25. Cannavo S., Arosio M., Vigo T. et al. Effects of the administration of PPAR-gamma receptor ligand - rosiglitazone on base line and CRH-stimulated ACTH and corti- sol levels in Cushing disease. Abstracts. ENEA Napoli, 2004.

26. Wagstaff A.J., Goa K.L. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs, 62: 1805-1837.

27. Basu R, Singh R.J., Basu A. et al. Splanchnic cortisol production occurs in humans. Diabetes, Vol. 53, 2004.

28. Walker B.R. Commentary: Is Cushing disease of the "omentum" an affliction of mouse and men? Diabetologia 47: 767-769, 2004.

29. Masuzaki H., Paterson J., Shinyama H. et al. A transgenic model f visceral obesity and the metabolic syndrome. Science 294: 2166-2170, 2001.

30. Bujalska I.J., Kumar S., Stewart P.M. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 349: 1210-1213, 1997.

Для цитирования:

Pigarova E.A., Dzeranova L.K., Galstyan G.R. Клинический случай применения Пиоглитазона при стероидном диабете у пациента с болезнью Иценко-Кушинга. Ожирение и метаболизм. 2005;2(3):25-28.

For citation:

., ., . Klinicheskiy sluchay primeneniya Pioglitazona pri steroidnom diabete u patsienta s bolezn'yu Itsenko-Kushinga. Obesity and metabolism. 2005;2(3):25-28. (In Russ.)

Просмотров: 12

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)